Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has issued its consolidated revenue guidance of KRW 4.16T for FY2024, which represents the midpoint of its projected YoY growth range (+10% to +15%).
📊 [Key Disclosure Details & Financial Figures]
- Outlook Classification: FY2024 Consolidated Business Performance Outlook (Unit: KRW 100M)
- Target Period: January 1, 2024 ~ December 31, 2024
- FY2024 Revenue Outlook: KRW 4,156.4B (KRW 4,156,400M)
- Operating Profit / Profit Before Income Tax / Net Profit Guidance: Not stated (-)
- Basis of Outlook: Market forecasts and business plan
- Basis for Figures: Midpoint of the expected revenue growth range (+10% to +15% YoY)
- Release Target & Date: Domestic and foreign investors / January 24, 2024 (Provided by IR Team)
- Previous Fiscal Year (FY2023) Guidance vs. Actual Performance (Variance Analysis):
- Target Period: January 1, 2023 ~ December 31, 2023
- FY2023 Revenue Guidance: KRW 3,601.6B / FY2023 Revenue Actual: KRW 3,694.6B (Error Rate: +2.6%)
- Other Remarks: Actual results may differ from forward-looking information due to changes in business environment or market conditions
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Actual Revenue Achievement and Potential Guidance Revisions
This disclosure provides advance fair disclosure regarding the company’s full-year revenue guidance for FY2024. Tracking whether quarterly actual results align with the projected annual revenue target of KRW 4.16T is essential to evaluate the execution of the business plan and corporate growth trajectory. Actual performance metrics and any revised guidance can be verified through subsequent quarterly disclosures titled ‘Provisional Performance (Consolidated Financial Results)’ and periodic reports.
📢 Disclaimer and Source Notice
Source: This content was structured and newly generated based on official submission data from the Financial Supervisory Service DART system.
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial liabilities rest entirely with the individual investor.
Contact: For regulatory compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
